GlassScriptPhysician profile
Daniel Lutwak
NPI 1366137085
$2,770.05
in general payments reported to CMS, 2019-2025
22 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $47.53 · 2024: $628 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.07 |
| Education | $246.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $365.83 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $339.12 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $288.05 | 2024-2025 | |
| Incyte Corporation | $229.42 | 2025 | Opzelura, Opzelura |
| Genzyme Corporation | $214.88 | 2025 | |
| Arcutis Biotherapeutics, INC. | $206.43 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $151.99 | 2024-2025 | |
| Lilly USA, LLC | $151.89 | 2024-2025 | Ebglyss, Taltz |
| Verrica Pharmaceuticals INC. | $121.01 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $95.25 | 2024 | Andexxa |
| Janssen Biotech, INC. | $94.99 | 2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $75.70 | 2024-2025 | |
| Botanix Sb INC | $74.26 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $74.16 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $73.42 | 2025 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $53.73 | 2024 | |
| Convatec INC. | $47.53 | 2023 | |
| Mallinckrodt Hospital Products INC. | $28.10 | 2024 | Acthar |
| Amgen INC. | $27.02 | 2025 | Otezla |
| Blueprint Medicines Corporation | $24.07 | 2025 | Ayvakit |
| Lnhc, INC | $16.67 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $16.53 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lutwak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.